A
Aristeia Capital, LLC
+ HoldingDMII
+3.11%
3M Return
$10.140
0.000 (0.00%)At close
Loading chart…
- High
- 10.140
- Open
- 10.140
- VWAP
- 10.14
- Vol
- 317.00
- Mkt Cap
- —
- Low
- 10.140
- Amount
- 3.21K
- EV/EBITDA, TTM
- 0.00
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenue to date.
AI analysis of Drugs Made In America Acquisition II Corp (DMII)
holdCurrently, DMII is not a strong buy due to its mixed financial performance and lack of significant momentum indicators. The stock is priced at $10.14, with an RSI of 56.83 indicating it is neither overbought nor oversold. However, the forward P/E ratio is 0, suggesting a lack of expected earnings growth, which is a concern for long-term investors.
Valuation Metrics
The current forward P/E ratio for Drugs Made In America Acquisition II Corp (DMII) is 0.00, compared to its 5-year average forward P/E of 0.00.
Whales holding DMII
DMII FAQ — answered by Alphio AI
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenue to date. It operates in the Financials sector.
Currently, DMII is not a strong buy due to its mixed financial performance and lack of significant momentum indicators. The stock is priced at $10.14, with an RSI of 56.83 indicating it is neither overbought nor oversold. However, the forward P/E ratio is 0, suggesting a lack of expected earnings growth, which is a concern for long-term investors.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。